03232017Headline:

Therapeutic drug monitoring tests will drive the therapeutic drug monitoring market growth in the next five years

In this report, the therapeutic drug monitoring market is broadly segmented by product, technology, class of drug, end user, and region. On the basis of product, the therapeutic drug monitoring market is divided into consumables and equipment. The equipment market is further segmented into immunoassay analyzers, proteomic equipment, and other equipment. On the basis of technology, the therapeutic drug monitoring market is categorized into three segments, namely, immunoassays, proteomic technologies, and others. The immunoassays segment is classified into chemiluminescent assay (CLIA), cloned enzyme donor immunoassay (CEDIA), fluorescence polarization immunoassay (FPIA), particle-enhanced turbidimetric inhibition immunoassay (PETINIA), and others. The proteomic technologies segment is further segmented into liquid chromatography/mass spectrometry and gas chromatography/mass spectrometry.

On the basis of class of drug, the therapeutic drug monitoring market is segmented into antiepileptics, antibiotics, immunosuppressants, antiarrhythmic drugs, bronchodilators, psychoactive drugs, and others. By end user, the therapeutic drug monitoring market is divided into hospital labs, commercial/private labs, and other end users.

The market is expected to grow at a decent pace in the next five to seven years owing to a number of factors such as the need for better healthcare in developing countries and rising prevalence of psychiatric diseases and cancer. However, high infrastructural costs and dearth of skilled resources may restraint the market growth.

North America is expected to account for more than half the therapeutic drug monitoring market share in 2015. It is the prime market for therapeutic drug monitoring due to the high awareness and acceptance of the benefits of therapeutic drug monitoring and growing healthcare expenditure. The market in Europe on the other hand is growing at a slower rate as the healthcare sector is recovering from the economic downturn and healthcare facilities are trying to minimize healthcare delivery costs. Growth in the APAC therapeutic drug monitoring market is comparatively slower due to lack of skilled healthcare personnel who can perform therapeutic drug monitoring tests with minimal errors.

Immunoassay analyzers, immunoassays, and assays for antiepileptics and antibiotics are the new revenue pockets for the therapeutic drug monitoring market.

What Next?

Recent Articles